Cite
MLA Citation
J Ettl et al.. “Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial.” Annals of oncology, vol. 29, 2018, pp. 1939–1947. http://access.bl.uk/ark:/81055/vdc_100095323065.0x00003d